A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Completed · Phase 3 · NCT05362058
Conditions: Diabetes, Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $2,449
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 928
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Insulin Efsitora Alfa (drug), Insulin Degludec (drug)
- Dates
- Started 2022-06-03; completion 2024-04-10
- Results posted
- Yes
The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. The study consists of a 1-week screening period, a 2-week lead-in period, a 52-week treatment period, and a 5-week safety follow-up period. The study will last up to 60 weeks.
From ClinicalTrials.gov, last updated 2025-05-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2,449 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ralph J. Duda JR., M.D. Endocrinology & Diabetes · Springfield, MO
- Awawu E. Igbinadolor, M.D. Adolescent Medicine · Monroe, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Monroe Biomedical Research $2,200
- Clinvest Research LLC $249
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.